Bcl-2 inhibitors induce cell death in primary patient CTCL cells and CTCL cell lines. (A-B) Specific cell death in primary CD4⁺ cells isolated from 6 healthy donors (control) and 6 patients with Sézary syndrome (patient) upon treatment with different concentrations of ABT-199 (A) or ABT-263 (B) for 24 hours. *P < .05 from respective healthy controls. (C-D) Specific cell death in J16, HH and SeAx cells upon treatment with different concentrations of ABT-199 (C) or ABT-263 (D) (n = 4, each) for 24 hours. *P < .05 from untreated control. (E) Relative Bcl-2 expression measured by qRTPCR in J16, SeAx and HH cells without stimulation. (F) Western blot analysis of Bcl-2 protein expression in J16, SeAx, and HH cells without stimulation.